1 completed. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Completed 1 |
Follow Undifferentiated Fallopian Tube Carcinoma: new trials by email Literature Review of Undifferentiated Fallopian Tube Carcinoma trials Research Report on Undifferentiated Fallopian Tube Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Bevacizumab, Cyclophosphamide, Laboratory Biomarker Analysis - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 2 | Completed | Roswell Park Cancer Institute | 40 | 2016-09-01 | 2021-10-06 |
Fallopian Tube Neoplasms (1) · Ovarian Neoplasms (1)
Adnexal Diseases (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Fallopian Tube Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genital Diseases (1) · Genital Diseases, Female (1) · Genital Neoplasms, Female (1) · Gonadal Disorders (1) · Neoplasms (1) · Neoplasms by Site (1) · Ovarian Diseases (1) · Urogenital Diseases (1) · Urogenital Neoplasms (1)
Bevacizumab (1) · Cyclophosphamide (1) · Disulfides (1) · Immunoglobulin G (1) · pembrolizumab (1)
Roswell Park Cancer Institute (1)
United States (1)
Emese Zsiros (1)